-
Mashup Score: 0Minimizing Glucocorticoid Use in Patients With ANCA-Associated Vasculitis | Docwire News - 17 hour(s) ago
A study found that combination cyclophosphamide and rituximab therapy for severe ANCA-associated vasculitis to minimize glucocorticoid use may reduce morbidity.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0
Proteinuria trajectory is a major predictor of disease progression in children and adults with IgA nephropathy (IgAN), a study found.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Identifying patients with #IgAN who are at risk for disease progression is critical—and #proteinuria trajectory is a major predictor. #nephrology #iganephropathy #nephtwitter https://t.co/ksZWoIWMpx https://t.co/RgX1hwKgvM
-
-
Mashup Score: 0
Rajiv Agarwal, MBBS, discussed a study showing that a finerenone and empagliflozin combination has superior efficacy at reducing UACR in chronic kidney disease and type 2 diabetes.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
✔️ Check out our interview with @AgarwalRajivMD, who presented at #ERA25 on the efficacy of pairing #finerenone and #empagliflozin to lower UACR. #nephtwitter #nephrology #kidneydisease #ckd #diabetes https://t.co/NXWSVTd9Xk https://t.co/OBPe1Lcov2
-
-
Mashup Score: 0
Dr. Richard Furie spoke with Nephrology Times about new data from the BLISS-LN study supporting the efficacy and safety of belimumab for active proliferative lupus nephritis (LN).
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
WATCH: Dr. Richard Furie spoke with us about a post hoc subgroup analysis of BLISS-LN in which belimumab demonstrated enhanced renal responses in lupus nephritis. #nephrology #nephtwitter #rheumatology #lupus #lupusnephritis #belimumab @NorthwellHealth https://t.co/nh95xIHSGu https://t.co/D2EpxhJozs
-
-
Mashup Score: 0Study Identifies microRNA-483-5p as Potential Biomarker for IgAN Progression | Docwire News - 3 day(s) ago
Research identified microRNA-483-5p as a possible biomarker for IgA nephropathy (IgAN) to help with risk stratification.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
The role of extracellular microRNAs in intercellular communication is gaining recognition for its role on inflammatory and scarring pathways in the kidneys. #microRNA #IgAN #IgAnephropathy #biomarkers #nephtwitter #nephrology https://t.co/Y4NyVAlBwN https://t.co/x561kJkx53
-
-
Mashup Score: 1
The race of patients with autosomal polycystic kidney disease (ADPKD) influences their waitlist experience, allograft quality, and post-transplant outcomes, a study found.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
How does race affect #transplantation outcomes for patients with #ADPKD? #kidneytransplantation #nephrology #nephtwitter #disparities https://t.co/JhUskK6IeA https://t.co/iuCXndJtsC
-
-
Mashup Score: 2
Phase 3 VISIONARY trial data presented at the ERA Congress 2025 showed sibeprenlimab helps achieve significant proteinuria reduction in patients with IgA nephropathy (IgAN).
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Interim results of VISIONARY presented in a late-breaking abstract at #ERA25 showed that #sibeprenlimab helps achieve significant #proteinuria reduction in patients with #IgAN. #IgAnephropathy #nephrology #nephtwitter @VladoPerkovic @ERAkidney https://t.co/1IKp7ciTcj https://t.co/rhAby9opYN
-
-
Mashup Score: 0Targeted-Release Budesonide Shows Benefit for Patients With Severe Renal Impairment | Docwire News - 5 day(s) ago
Nefecon, a targeted-release form of budesonide, can safely be used to treat severe renal impairment and lowers proteinuria in patients with IgA nephropathy (IgAN), a study found.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
A study examined the use of #Nefecon, a targeted-release #budesonide formulation, in patients with #IgAN and severe renal impairment. #iganephropathy #nephrology #nephtwitter https://t.co/sp7KlLYaXW https://t.co/ubZoJbLGwH
-
-
Mashup Score: 0Award Recipients Honored at 62nd ERA Congress | Docwire News - 6 day(s) ago
Winners of the 2025 European Renal Association (ERA) Awards and ERA Awards for Young Investigators were recognized at the 62nd ERA Congress in Vienna, Austria.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
Outstanding contributors to the field of #nephrology were honored during a ceremony at #ERA25. #nephtwitter @ERAkidney https://t.co/Rp65tVgRH3 https://t.co/sQzBgQmEuj
-
-
Mashup Score: 0Using Serum Cystatin C in Diagnosis of AKI | Docwire News - 7 day(s) ago
Using serum cystatin C (sCys) as a biomarker for acute kidney injury (AKI) could prove to be a valuable addition to diagnostic protocols, a study reports.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
How does sCys compare to sCr for timely diagnosis of AKI? #acutekidneyinjury #nephrology #nephtwitter #cystatin #creatinine https://t.co/AHjbCkGECn https://t.co/CamCorX7JM
-
Cyclophosphamide-rituximab therapy and minimal use of glucocorticoids in ANCA-associated vasculitis may reduce morbidity. #AAV #ANCAvasculitis #nephrology #rituximab #cyclophosphamide #glucocorticoids https://t.co/tBTm8YuCHR https://t.co/kpiKth1sw7